147 results about "Infarction" patented technology

The invention discloses a deep learning-based stroke prognosis prediction method and system. The method comprises the steps of obtaining a head magnetic resonance medical image data set of a stroke patient before treatment and a corresponding mRS score of stroke prognosis; segmenting a core infarction focus image from the obtained magnetic resonance medical image by adopting a DWI sequence; establishing a six-score cSVD load scoring standard, scoring the core infarction focus image, and constructing a model data set; 3, constructing a prediction model for predicting the stroke prognosis mRS score, dividing the model data set in the step 3 into a training set, a verification set and a test set, training the prediction model by adopting the training set, verifying the prediction model on the verification set, testing by adopting the test set, screening out the prediction model of which the precision meets the requirement, and determining the stroke prognosis mRS score. And predicting the mRS score of the stroke prognosis of the to-be-evaluated patient by adopting the screened prediction model. According to the method, the prediction capability of the image features obtained by MRI (Magnetic Resonance Imaging) flat scanning of the LAA-AIS patient on prognosis is fully excavated, and a new reference direction is provided for prognosis evaluation of the LAA-AIS patient.

The invention discloses a stroke prognosis prediction method and system, and the method comprises the steps: S1, obtaining a CTP image of a whole cerebral vessel; and S2, the CTP image is segmented, and the segmented CTP image is obtained. And S3, carrying out feature extraction on the segmented CTP image to respectively obtain morphological features of whole cerebral vessels, perfusion features of an infarction core region and blood flow difference features of key blood vessel points. And S4, constructing a stroke prognosis prediction model based on machine learning according to the morphological characteristics of the whole brain blood vessels, the infarct core region perfusion characteristics and the blood flow difference characteristics of the key blood vessel points. According to the method, the blood flow and perfusion characteristics of the blood vessel are extracted more comprehensively, finely and quantitatively, and the whole method and system are full-automatic and do not need manual participation.

The invention discloses injectable hydrogel with redox activity and electroactivity as well as a preparation method and application of the injectable hydrogel, and belongs to the technical field of medical materials. The preparation method comprises the following steps: reacting methacrylic anhydride and polysaccharide molecules in a solvent to prepare a double-bond functional polymer; the preparation method comprises the following steps: firstly, pre-polymerizing dopamine in a solvent, and then adding MOF (Metal Organic Framework) to carry out polymerization reaction, so as to prepare dopamine modified MOF; reacting the dopamine modified MOF, EDOT and ferric salt in a solvent, and collecting the precipitate to prepare a nano filler; the preparation method comprises the following steps: jointly dispersing the double-bond functional polymer, active polypeptide, a photoinitiator and nano filler into a solvent, and carrying out photocuring cross-linking. The preparation condition is mild, gel forming is rapid, the method is simple, the prepared hydrogel has injectable performance and conductive performance, catalytic activity of natural enzyme can be simulated, active oxygen removal can be achieved in the early stage of myocardial ischemia, electrical conduction of infarction parts can be enhanced, and effective recovery of cardiac functions can be achieved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

The invention discloses a construction method of a cerebral artery ischemia reperfusion model, and belongs to the technical field of animal models. Three-dimensional positioning coordinates of the middle cerebral artery are obtained through magnetic resonance scanning, the far end of the middle cerebral artery can be accurately positioned, the middle cerebral artery is induced to be blocked after irradiation by setting the blood vessel irradiation position, the rose red dosage and the laser irradiation intensity and time, blood vessel recanalization is caused along with blood impact within 4-5 hours, and finally an ischemia reperfusion model is formed. Compared with a traditional craniotomy electrocoagulation middle cerebral artery (permanent occlusion) and a traditional balloon embolism middle cerebral artery (ischemia reperfusion), the construction method has the advantages that wounds on animals are smaller, the animals are easy to survive, and compared with traditional photochemical induction which can only form infarction lesions on the surface layer of the brain, the method can induce deep brain tissue to form infarction, so that the method has the advantages of being simple and convenient to operate and the like. The method can also be expanded to other brain areas to induce deep vascular occlusion. Meanwhile, the method is also suitable for carrying out model construction on old animals, and the modeling success rate is increased.

The invention discloses a hydrogel-acellular matrix composite patch containing functionalized extracellular vesicles and a preparation method of the hydrogel-acellular matrix composite patch. The composite patch comprises a hydrogel layer and an acellular pericardium matrix material layer, and an extracellular vesicle-macrophage membrane fusion body (EV-MM) is entrapped in the cross-linked hydrogel. From two aspects of improving the targeting of EVs to the cardiac infarction part and enhancing the retention of the EVs at the cardiac infarction part, the distribution condition of the EVs at the cardiac infarction part is improved, so that the action efficiency of the EVs is improved, and the treatment effect is improved.

The invention relates to the technical field of artificial intelligence, in particular to an acute ischemic stroke infarction core area expansion risk prediction system, which comprises an acquisition module for acquiring head MRI-DWI images and clinical information of a patient; the first prediction module is used for predicting the expansion risk of an infarction core region according to the clinical information and the head MRI-DWI image; and the second prediction module is used for marking an expanded area of the infarction core area according to the head MRI-DWI image. In order to solve the problem that an image processing scheme in the prior art is low in diagnosis efficiency improvement, two models are introduced to effectively process multi-modal information composed of a head MRI-DWI image of a patient and clinical information, the possibility of further progression of the condition of the patient according to the current multi-modal information is predicted, and the probability of further progression of the condition of the patient according to the current multi-modal information is predicted. When the infarction core area is expanded, the range is possibly expanded on the image, and the prediction range and the quantitative evaluation result of the infarction core area are visually displayed on the primary diagnosis MRI-DWI sequence, so that a doctor can make further diagnosis conveniently.

The invention belongs to the technical field of biology, and particularly relates to a compound for treating myocardial infarction. The chondroitin sulfate oligosaccharide is extracted from natural chondroitin sulfate, and after the chondroitin sulfate oligosaccharide is treated into an oligosaccharide chain through a chemical enzyme method, experiments prove that the chondroitin sulfate oligosaccharide is beneficial to the survival of myocardial cells. Compared with other products with similar functions, the glycopeptide polymer hydrogel formed after introduction of the polymer skeleton overcomes the problem of batch-to-batch difference of natural products and is clear in structure, and the hydrogel has excellent biological activity and does not need to entrap other active ingredients such as drugs. The effects of supporting the ventricular wall of the infarction region and promoting the survival of myocardial cells are obvious, the myocardial infarction area can be effectively limited, the thickness of the ventricular wall of the infarction region is increased, the damage of myocardial infarction to the heart is reduced, and the application prospect is very good.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The invention relates to application of piRNA-AB352916 and a mimetic thereof in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of medicines. In order to solve the problem that a medicine capable of promoting myocardial cell proliferation and inhibiting myocardial cell apoptosis is lacked in the treatment process of the ischemic heart disease, the invention provides application of piRNA-AB352916 and a mimetic thereof in preparation of a medicine for treating the ischemic heart disease. According to the application disclosed by the invention, the expression level of the piRNA-AB352916 in myocardial regeneration model tissues after cardiac apex resection is obviously increased, and animal experiments prove that the myocardial specific overexpression piRNA-AB352916 not only can promote myocardial cell proliferation, but also can inhibit myocardial cell apoptosis, so that the myocardial infarction area is reduced, and the cardiac function of an infarction mouse is improved. The invention proves that the piRNA-AB352916 and the analogue thereof have prevention and treatment values on the ischemic heart disease.

The embodiment of the invention discloses an acute ischemic stroke collateral circulation noninvasive assessment method and device. The method comprises the steps of obtaining a CTP data set and a DSA data set of different collateral circulation levels, constructing an image segmentation model based on a space-modal attention network and an intracranial artery blood supply partition model based on an atlas, subdividing and extracting different areas of the ischemic side from the angles of perfusion function and vascular structure, and taking a DSA score as a gold standard, combining perfusion function quantitative information and vascular structure quantitative information in each region after ischemic side subdivision to construct a collateral circulation scoring model; and taking perfusion function quantitative information and vascular structure quantitative information of each artery blood supply region, the lateral split region, the infarction core region and the penumbra on the ischemic side as input and model training, and predicting to obtain an individual collateral circulation scoring result. According to the method, the non-invasive evaluation accuracy of collateral circulation can be improved by jointly analyzing the perfusion function and the blood vessel structure information provided by the CTP.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

A system and method of measurement and calculation of intracardiac pressures based on non-invasive medical imaging is presented, wherein the pressure measurements are performed by means of the image stream with further estimation of the volumes of oscillating traceable regions within the heart vicinity. The volume estimates are tied to pressure values in such oscillating traceable regions as left / right atria and ventricles, pulmonary artery and aorta. The invention permits to assess non-invasively and in real time the pressure in any part of the heart and large blood vessels, and calculate the major markers of heart failure, cardiomyopathy, ventricular ischemia, infarction and other heart related diseases.

The present invention relates to a cholecystokinin (CCK) antagonist for use in the prevention and / or treatment of a vestibular disease or disorder selected from motion sickness, Meniere's disease, vestibular migraine, disembarkment sickness, labyrinthitis, vestibular neuronitis, benign paroxysmal positional vertigo, labyrinthine infarction and nausea.

The invention relates to an accurate evaluation and dynamic optimization system for cerebral infarction ultra-early reperfusion treatment, in particular to the field of biomedicine.Heterogeneous image data are fused through multi-center federal learning, and a high-robustness standardized brain characteristic spectrum is constructed; the real-time physiological parameters are utilized to drive the dynamic graph network, and the pathological process of the ischemic penumbra evolved along with time is accurately simulated; a core infarction zone and half-dark band probability graph with reasonable spatial distribution is generated by introducing a multi-task classifier with mutual exclusion constraints; and finally, a virtual contrast perfusion image is generated in combination with the individual blood vessel conditions of the patient to perform personalized calibration, so that the accuracy and individualization level of the delineation of the penumbra are remarkably improved, more reliable and dynamic decision support is provided for a clinician to formulate an ultra-early reperfusion treatment scheme, and the risk of insufficient treatment or excessive treatment is effectively avoided.

The invention belongs to the field of biological medicines, and provides a construction method of a photochemically induced mouse cerebral ischemia model, which comprises the following steps: S1, inducing anesthesia of a mouse, and ensuring that the mouse is continuously in an anesthesia state; s2, in the lateral position of the mouse, unhairing and disinfecting the face on one side, and cutting from the face of the mouse to expose the proximal end position of the M3 segment of the middle cerebral artery of the mouse or the cross point of reverse extension lines of branch blood vessels of the middle cerebral artery; s3, injecting a photosensitizer into the mouse, and after the photosensitizer circulates uniformly in the body of the mouse, irradiating the proximal end of the M3 segment of the middle cerebral artery or the cross point of the reverse extension line of the branch blood vessel of the middle cerebral artery after laser focusing; s4, after laser irradiation is finished, the skin is sutured, anesthesia is stopped, and the wound of the mouse is coated with an analgesic. The model obtained by the construction method of the photochemically induced mouse cerebral ischemia model provided by the invention has a larger infarct volume, and the infarct invades the subcortical brain region, so that the pathological characteristics of ischemic brain tissues are more obvious.

The invention discloses an application of a non-contact electrical stimulation assembly in preparation of a myocardial infarction repair system, and the non-contact electrical stimulation assembly is a PLLA film, potassium sodium niobate nanoparticles or a PLLA film doped with the potassium sodium niobate nanoparticles. The non-contact electrical stimulation assembly generates an electric field through ultrasonic wireless driving so as to electrically stimulate infarction myocardial tissue. The PLLA film and the potassium sodium niobate nanoparticles in the non-contact electrical stimulation assembly are piezoelectric materials which do not contain lead, are good in biocompatibility and are degradable, and have higher clinical conversion value; an electric field is generated through ultrasonic wireless driving, then infarction myocardial tissue is electrically stimulated, myocardial infarction repair is promoted, ventricular remodeling is inhibited, and the problem that traditional electrical stimulation depends on invasive electrode implantation, a patient needs to carry the electrode for a long time, and then the life quality of the patient is affected is solved. Different modes of electrical stimulation can be given to cardiac muscle tissues according to requirements, and application is flexible.

The invention discloses an application of sulfonated saccharide hydrogel containing sulfonated saccharide and a hydrogel matrix material in prevention and / or treatment of myocardial infarction. Specifically, the invention provides application of sulfonated saccharide hydrogel containing sulfonated saccharide and a hydrogel matrix material, and the sulfonated saccharide hydrogel is used for preparing a pharmaceutical composition for preventing and / or treating myocardial infarction. Wherein the molecular weight of the sulfonated saccharide is 1000Da-300000Da, the sulfur content is 0.5-30%, and the hydrogel matrix material comprises an extracellular matrix material and a derivative thereof. The sulfonated saccharide hydrogel can effectively promote neovascularization and cardiac function recovery after myocardial infarction under the condition that exogenous cells or growth factors are not introduced, ventricular hypertrophy and fibrosis degree in the later stage of infarction are remarkably inhibited, and a new thought is provided for clinical myocardial infarction transformation treatment.

An apparatus for providing access to a patient's vasculature according to one aspect of the present invention comprises a dilator having a distal tip, a proximal end and a main body extending therebetween. The dilator includes a first lumen extending from the proximal end to the distal tip and a second lumen extending in parallel to the first lumen between the proximal end and a side port provided in the main body spaced proximal to the distal tip by a distance. The apparatus further comprises a first hemostasis valve in fluid communication with the first lumen at the proximal end of the dilator and a second hemostasis valve in fluid communication with the second lumen at the proximal end of the dilator. A retrograde guidewire is provided positionable within the first lumen of the dilator for advancement therein from the proximal end toward the distal tip and adapted to project therefrom by a first preselected distance. A deflection microcatheter is also provided positionable within the second lumen for advancement therein from the proximal end toward the side port and adapted to project therefrom by a second preselected distance and an antegrade guidewire positionable within a lumen of the deflection microcatheter for advancement therein from the proximal end toward the side port and adapted to project therefrom by a third preselected distance.

Infarction damage is ameliorated or treated through the administration of a mitochondrial degradation inhibitor, such as one that acts by inhibiting translocation of one or more molecules across a mitochondrial membrane, for example BAX / BNIP3 complexes involved in mitochondrial degradation. By preventing mitochondrial degradation, one allows more efficient oxygenation of an infarcted region, allowing for a greater degree of cell survival and a more successful recovery.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 neuron cells and hCMEC / D3 brain microvascular endothelial cells injured by oxygen-glucose deprivation (OGD) induction, and can resist the injury of PC12 cells induced by corticosterone (CORT) and MPP + , and effectively inhibit the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, and can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve and vascular units.

The invention relates to the technical field of intelligent early warning, in particular to a wrist-wearing type acute infarction disease heart symptom home early warning system which comprises a signal alignment module, a feature association module, a trend recognition module, a risk triggering module and an event feedback module, and based on an electric pulse signal waveform, the occurrence time node of an R wave is judged to serve as a reference. Synchronous acquisition and unified time sequence processing of multichannel signals are realized, electrocardiogram, skin conductance and micro blood flow data are integrated on the basis of the same cardiac reference point, a time window-oriented multi-factor dynamic comparison structure is constructed, the trend relationship among multiple parameters is identified through correlation analysis, and the accuracy of the comparison result is improved. A threatened characteristic period is accurately positioned by means of a common pattern screening mechanism, real-time monitoring and historical comparison are integrated in a feedback process, data cyclic utilization is enhanced, multi-source signal dynamic collaborative judgment is realized, the timeliness and stability of risk identification are further improved, and the high-confidence early warning requirement of home health monitoring is effectively met.

The invention relates to a coronary microcirculation disturbance examination technology in non-occlusive coronary diseases, and aims to objectively evaluate the myocardial ischemia degree of angina pectoris patients without occlusive coronary diseases and quantify the myocardial ischemia range caused by microcirculation disturbance through a load dynamic myocardial perfusion imaging (MPI) technology. Siemens third-generation double-source CT is adopted, a coarse pitch scanning mode is utilized, a one-stop CCTA combined MPI technology is achieved, the problem that the radiation dosage is too high is solved, and meanwhile the detection rate of myocardial ischemia is increased. Indexes such as myocardial blood flow (MBF), myocardial blood volume (MBV), time of arrival (TTP), coronary artery blood flow reserve (CFR) and the like of angina pectoris patients and healthy volunteers are compared, and changes of myocardial ischemia areas are objectively evaluated. The degree and range of microcirculation disturbance are quantitatively evaluated, and an infarction region and an ischemic region are identified. Quantitative evaluation is carried out on coronary artery microcirculation of the angina pectoris patient in clinical work, and a basis is provided for early intervention.

The invention relates to a method for improving myocardial protection activity of human embryonic stem cell exosomes and application of the method, and belongs to the technical field of biological medicine. In order to solve the problem of low biological activity of embryonic stem cell exosomes extracted through in-vitro culture, the invention provides a method for improving myocardial protection activity of human embryonic stem cell exosomes, when human embryonic stem cells are subcultured until the confluence degree reaches 70-80%, green light is used as a unique light source to vertically irradiate the human embryonic stem cells for a certain period of time, and the human embryonic stem cell exosomes are obtained. Continuing to culture the human embryonic stem cells subjected to light stimulation, and centrifugally extracting the exosomes generated by the human embryonic stem cells. According to the method, the yield of the human embryonic stem cell exosome is increased, the myocardial protection activity of the human embryonic stem cell exosome is remarkably improved, and the exosome generated by the human embryonic stem cell irradiated by green light can remarkably promote myocardial cell proliferation, inhibit myocardial cell apoptosis caused by hypoxia, reduce the myocardial infarction area and recover the infarction heart function.

The invention discloses a traditional Chinese medicine composition for treating cerebral infarction. The composition is prepared from the following raw materials in parts by weight: 15-25 parts of arisaema cum bile, 15-25 parts of bulbus fritillariae thunbergii, 10-20 parts of rhizoma gastrodiae, 10-15 parts of rhizoma atractylodis macrocephalae, 10-15 parts of radix paeoniae alba, 15-20 parts of ligusticum wallichii, 15-20 parts of caulis spatholobi, 20-30 parts of herba lycopi, 10-15 parts of coptis chinensis, 10-15 parts of rhizoma acori graminei, 10-20 parts of ginseng and 5-10 parts of lumbricus. The traditional Chinese medicine composition is reasonable in compatibility according to etiology and pathogenesis of cerebral infarction, all the medicines jointly achieve the effects of promoting blood circulation, removing blood stasis, descending turbidity, extinguishing wind, eliminating phlegm and dredging collaterals, cerebral tissue infarction and neurological function impairment can be obviously improved, and the action mechanism of the traditional Chinese medicine composition is related to cerebral tissue inflammatory response relieving, oxidative stress inhibiting and the like.

The invention discloses an application of a Ptbp2 accelerant in treatment of cerebral arterial thrombosis. It is found for the first time that overexpressed Ptbp2 can remarkably improve the neurological function of a mouse with the cerebral arterial thrombosis, reduce the infarct volume and relieve neuroinflammation mediated by microglia, and the overexpressed Ptbp2 can be used for effective treatment of the cerebral arterial thrombosis. The invention provides a theoretical basis for research and development of drugs for treating cerebral arterial thrombosis, opens up the application of the Ptbp2 accelerant, provides a brand new method for treating cerebral arterial thrombosis, and has a wide application prospect in the technical field of cerebral arterial thrombosis treatment.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

The invention discloses a fusion oligopeptide. The fusion oligopeptide is formed by fusing a cell-penetrating peptide and an oligopeptide for inhibiting combination of MD2 and CIRP. The invention also discloses an application of the fusion oligopeptide in preparation of a medicine for treating central nervous cell diseases mediated by an MD2-TLR4 signal channel. The fusion oligopeptide provided by the invention only has 15 amino acids, not only reduces immunological rejection of an organism, but also is relatively low in synthesis cost, and is used as a bioactive molecule to effectively block central nervous cell disease injury mediated by an MD2-TLR4 signal channel, relieve post-stroke nerve injury caused by nerve excitation toxicity and reduce infarct area, so that the fusion oligopeptide can be used as a biologically active molecule to effectively inhibit apoplexy. The nerve function is effectively recovered.

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.